Abcam, ab168432, Anti-PDE9A antibody

Size: 50µg
Mouse Polyclonal PDE9A antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human PDE9A.
Key facts
Host species:Mouse,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Full Length Protein corresponding to Human PDE9A.O76083

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PDE9A is a phosphodiesterase enzyme that breaks down cyclic guanosine monophosphate (cGMP) into non-cyclic GMP therefore regulating intracellular levels of cGMP. This enzyme has a molecular mass of approximately 65 kilodaltons. Researchers often refer to PDE9A also as phosphodiesterase 9A. It shows higher expression in the brain and heart with presence also noted in the kidneys and lungs.
Biological function summary
PDE9A regulates the signaling processes by controlling cGMP turnover. It functions as a part of a larger network of proteins involved in intracellular signal transduction. PDE9A does not typically form distinct complexes but interacts with signaling components to maintain balanced cGMP concentrations which is essential for signaling related to vasodilation and platelet aggregation.
Pathways
PDE9A influences both cardiovascular and central nervous system pathways. In the cardiovascular system it interacts with nitric oxide signaling which has connections to blood pressure regulation through vasodilation. Within the CNS PDE9A is involved in synaptic plasticity relating to proteins like phosphodiesterase PDE5 and PDE2 which also handle cyclic nucleotide breakdown affecting neurotransmitter signaling and learning processes.
PDE9A has connections to conditions like heart failure and Alzheimer’s disease. In heart failure PDE9A’s regulation of cGMP affects nitric oxide signaling and cardiac function. In Alzheimer’s disease its influence on synaptic plasticity through interactions with proteins like amyloid precursor protein (APP) suggests a role in cognitive decline making it a potential therapeutic target for modulating synaptic signaling and cognitive function.